Search

Bamlanivimab

for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. … it in collaboration with Eli Lilly and Company.

Thimerosal

Although thimerosal is banned in several countries, it continues to be included as a preservative in some vaccines in the United States and many vaccines in the developing world [L1685]. … Developed in 1927, thimerosal has been and is still being used as a preservative in some cosmetics, topical pharmaceuticals, and biological drug products, which includes vaccines.

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … , which may alter patient responses in the experimental and placebo groups; and patient populations were largely homogenous, which may have increased the odds of success of the trial.

Contulakin-G

Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

Glimepiride

[A177703] Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM. … Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular

Bafilomycin A1

These compounds all appear in the same fermentation and have similar biological activity. Bafilomycins are specific inhibitors of vacuolar-type H+-ATPase. (V-ATPase). … The most commonly utilized bafilomycin is bafilomycin A1. This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

Cholestyramine

Cholestyramine resin is quite hydrophilic, but insoluble in water. … Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins.

Emicizumab

The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents. … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.

Sodium molybdate

Enzalutamide

[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.